Research advances in tumor-infiltrating lymphocytes in treatment of biliary tract cancer

Xueshuai WAN; Xiaobing XIE; Haitao ZHAO; Weiyue GU; Henghui ZHANG

doi:10.3969/j.issn.1001-5256.2023.05.005

Volume 39 Issue 5

May 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(5): 1030-1036

PDF( 1885 KB)

Research advances in tumor-infiltrating lymphocytes in treatment of biliary tract cancer

DOI: 10.3969/j.issn.1001-5256.2023.05.005

1.
Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China
2.
Chineo Therapeutics Co., Ltd., Beijing 101111, China
3.
Beijing Immupeutics Medicine Technology Co., Ltd., Beijing Engineering Research Center of Immunocellular Therapy, Beijing 102600, China

Research funding:

National High Level Hospital Clinical Research Funding (2022-PUMCH-B-128);

CAMS Innovation Fund for Medical Sciences(CIFMS) (2022-I2M-C & T-A-003);

CAMS Innovation Fund for Medical Sciences (CIFMS) (2021-I2M-1-061);

CAMS Innovation Fund for Medical Sciences (CIFMS) (2021-I2M-1-003);

CSCO-MSD Cancer Research Fund (Y-MSDZD2021-0213);

CSCO-Hengrui Cancer Research Fund (Y-HR2019-0239);

CSCO-Hengrui Cancer Research Fund (Y-HR2020MS-0415);

CSCO-Hengrui Cancer Research Fund (Y-HR2020QN-0414);

National Ten-thousand Talent Program

More Information

Corresponding author: ZHAO Haitao, zhaoht@pumch.cn (ORCID: 0000-0002-3444-8044)
Received Date: 2023-03-10
Accepted Date: 2023-04-11
Published Date: 2023-05-20

Abstract

Abstract

Tumor-infiltrating lymphocytes (TILs) are a heterogeneous subset of lymphocytes, mainly T cells, present in tumor parenchyma and stroma. After being digested and isolated from tumor tissue and then cultured in vitro for activation and multiplication, it can be infused back into the patient's body to kill tumor cells. TILs have the advantages of high diversity of TCR, excellent ability to infiltrate into tumor sites, and low toxicity and are considered promising for the treatment of malignant solid tumors. At present, TIL therapy has been tested as a second-line treatment in a variety of solid tumors and has achieved preliminary results. Although there is still no clinical cohort report on the application of TILs in biliary tract cancer (BTC), recent clinical reports on multiple cancers have provided information on the efficacy of TIL therapy in a small number of BTC patients, which preliminarily confirmed the safety and efficacy of TIL therapy. However, since BTC is generally considered an immunologically repulsive tumor in which most effector T cells are sequestered at the tumor edge, the antitumor effect of TILs in BTC remains difficult to predict. Combination therapy with different anti-tumor methods and the development of new techniques to modify cells to enhance the anti-tumor ability of TILs are possible directions for breakthrough in the future.
- Lymphocytes, Tumor-Infiltrating,
- Biliary Tract Neoplasms,
- Therapeutics

FullText(HTML)

References(42)

References

[1]	SASADA T, SUEKANE S. Variation of tumor-infiltrating lymphocytes in human cancers: controversy on clinical significance[J]. Immunotherapy, 2011, 3(10): 1235-1251. DOI: 10.2217/imt.11.106.
[2]	RASKOV H, ORHAN A, CHRISTENSEN JP, et al. Cytotoxic CD8⁺ T cells in cancer and cancer immunotherapy[J]. Br J Cancer, 2021, 124(2): 359-367. DOI: 10.1038/s41416-020-01048-4.
[3]	WIEDEMANN A, DEPOIL D, FAROUDI M, et al. Cytotoxic T lymphocytes kill multiple targets simultaneously via spatiotemporal uncoupling of lytic and stimulatory synapses[J]. Proc Natl Acad Sci U S A, 2006, 103(29): 10985-10990. DOI: 10.1073/pnas.0600651103.
[4]	ABIKO K, MATSUMURA N, HAMANISHI J, et al. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer[J]. Br J Cancer, 2015, 112(9): 1501-1509. DOI: 10.1038/bjc.2015.101.
[5]	AHMADZADEH M, JOHNSON LA, HEEMSKERK B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired[J]. Blood, 2009, 114(8): 1537-1544. DOI: 10.1182/blood-2008-12-195792.
[6]	INOZUME T, HANADA K, WANG QJ, et al. Selection of CD8⁺PD-1⁺ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells[J]. J Immunother, 2010, 33(9): 956-964. DOI: 10.1097/CJI.0b013e3181fad2b0.
[7]	EBERLEIN TJ, ROSENSTEIN M, ROSENBERG SA. Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2[J]. J Exp Med, 1982, 156(2): 385-397. DOI: 10.1084/jem.156.2.385.
[8]	ROSENBERG SA, SPIESS P, LAFRENIERE R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes[J]. Science, 1986, 233(4770): 1318-1321. DOI: 10.1126/science.3489291.
[9]	ROSENBERG SA, YANG JC, SHERRY RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy[J]. Clin Cancer Res, 2011, 17(13): 4550-4557. DOI: 10.1158/1078-0432.CCR-11-0116.
[10]	ROSENBERG SA, PACKARD BS, AEBERSOLD PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report[J]. N Engl J Med, 1988, 319(25): 1676-1680. 10.1056/NEJM198812223192527. DOI: 10.1056/NEJM198812223192527
[11]	SHARMA P, HU-LIESKOVAN S, WARGO JA, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy[J]. Cell, 2017, 168(4): 707-723. DOI: 10.1016/j.cell.2017.01.017.
[12]	SIM M, SUN PD. T cell recognition of tumor neoantigens and insights into T cell immunotherapy[J]. Front Immunol, 2022, 13: 833017. DOI: 10.3389/fimmu.2022.833017.
[13]	KRISTENSEN NP, HEEKE C, TVINGSHOLM SA, et al. Neoantigen-reactive CD8⁺ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma[J]. J Clin Invest, 2022, 132(2): e150535. DOI: 10.1172/JCI150535.
[14]	RATTO GB, ZINO P, MIRABELLI S, et al. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma[J]. Cancer, 1996, 78(2): 244-251. DOI: 10.1002/(SICI)1097-0142(19960715)78:2<244::AID-CNCR9>3.0.CO;2-L.
[15]	XING Y, YASINJAN F, DU Y, et al. Immunotherapy in cervical cancer: From the view of scientometric analysis and clinical trials[J]. Front Immunol, 2023, 14: 1094437. DOI: 10.3389/fimmu.2023.1094437.
[16]	STEVANOVIĆ S, DRAPER LM, LANGHAN MM, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells[J]. J Clin Oncol, 2015, 33(14): 1543-1550. DOI: 10.1200/JCO.2014.58.9093.
[17]	DENG M, RAN P, CHEN L, et al. Proteogenomic characterization of cholangiocarcinoma[J]. Hepatology, 2023, 77(2): 411-429. DOI: 10.1002/hep.32624.
[18]	HYDER O, HATZARAS I, SOTIROPOULOS GC, et al. Recurrence after operative management of intrahepatic cholangiocarcinoma[J]. Surgery, 2013, 153(6): 811-818. DOI: 10.1016/j.surg.2012.12.005.
[19]	ZHOU G, SPRENGERS D, MANCHAM S, et al. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules[J]. J Hepatol, 2019, 71(4): 753-762. DOI: 10.1016/j.jhep.2019.05.026.
[20]	GOEPPERT B, FRAUENSCHUH L, ZUCKNICK M, et al. Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer[J]. Br J Cancer, 2013, 109(10): 2665-2674. DOI: 10.1038/bjc.2013.610.
[21]	LIU D, HEIJ LR, CZIGANY Z, et al. The role of tumor-infiltrating lymphocytes in cholangiocarcinoma[J]. J Exp Clin Cancer Res, 2022, 41(1): 127. DOI: 10.1186/s13046-022-02340-2.
[22]	VIGANO L, SOLDANI C, FRANCESCHINI B, et al. Tumor-infiltrating lymphocytes and macrophages in intrahepatic cholangiocellular carcinoma. Impact on prognosis after complete surgery[J]. J Gastrointest Surg, 2019, 23(11): 2216-2224. DOI: 10.1007/s11605-019-04111-5.
[23]	OSHIKIRI T, MIYAMOTO M, SHICHINOHE T, et al. Prognostic value of intratumoral CD8⁺ T lymphocyte in extrahepatic bile duct carcinoma as essential immune response[J]. J Surg Oncol, 2003, 84(4): 224-228. DOI: 10.1002/jso.10321.
[24]	WOO SR, CORRALES L, GAJEWSKI TF. The STING pathway and the T cell-inflamed tumor microenvironment[J]. Trends Immunol, 2015, 36(4): 250-256. DOI: 10.1016/j.it.2015.02.003.
[25]	KATHER JN, SUAREZ-CARMONA M, CHAROENTONG P, et al. Topography of cancer-associated immune cells in human solid tumors[J]. Elife, 2018, 7: e36967. DOI: 10.7554/eLife.36967.
[26]	ZHOU M, WANG C, LU S, et al. Tumor-associated macrophages in cholangiocarcinoma: complex interplay and potential therapeutic target[J]. EBioMedicine, 2021, 67: 103375. DOI: 10.1016/j.ebiom.2021.103375.
[27]	BRAHMER JR, TYKODI SS, CHOW LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer[J]. N Engl J Med, 2012, 366(26): 2455-2465. DOI: 10.1056/NEJMoa1200694.
[28]	YOON JG, KIM MH, JANG M, et al. Molecular characterization of biliary tract cancer predicts chemotherapy and programmed death 1/programmed death-ligand 1 blockade responses[J]. Hepatology, 2021, 74(4): 1914-1931. DOI: 10.1002/hep.31862.
[29]	GOEPPERT B, ROESSLER S, RENNER M, et al. Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma[J]. Br J Cancer, 2019, 120(1): 109-114. DOI: 10.1038/s41416-018-0199-2.
[30]	NAKAMURA H, ARAI Y, TOTOKI Y, et al. Genomic spectra of biliary tract cancer[J]. Nat Genet, 2015, 47(9): 1003-1010. DOI: 10.1038/ng.3375.
[31]	SAWASDEE N, THEPMALEE C, SUJJITJOON J, et al. Gemcitabine enhances cytotoxic activity of effector T-lymphocytes against chemo-resistant cholangiocarcinoma cells[J]. Int Immunopharmacol, 2020, 78: 106006. DOI: 10.1016/j.intimp.2019.106006.
[32]	MORISAKI T, UMEBAYASHI M, KIYOTA A, et al. Combining cetuximab with killer lymphocytes synergistically inhibits human cholangiocarcinoma cells in vitro[J]. Anticancer Res, 2012, 32(6): 2249-2256.
[33]	KVERNELAND AH, CHAMBERLAIN CA, BORCH TH, et al. Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types[J]. J Immunother Cancer, 2021, 9(10): e003499. DOI: 10.1136/jitc-2021-003499.
[34]	TRAN E, TURCOTTE S, GROS A, et al. Cancer immunotherapy based on mutation-specific CD4⁺ T cells in a patient with epithelial cancer[J]. Science, 2014, 344(6184): 641-645. DOI: 10.1126/science.1251102.
[35]	PRICKETT TD, CRYSTAL JS, COHEN CJ, et al. Durable complete response from metastatic melanoma after transfer of autologous T cells recognizing 10 mutated tumor antigens[J]. Cancer Immunol Res, 2016, 4(8): 669-678. DOI: 10.1158/2326-6066.CIR-15-0215.
[36]	TRAN E, ROBBINS PF, LU YC, et al. T-Cell transfer therapy targeting mutant KRAS in cancer[J]. N Engl J Med, 2016, 375(23): 2255-2262. DOI: 10.1056/NEJMoa1609279.
[37]	KOUKOURAKIS IM, GKEGKA AG, XANTHOPOULOU E, et al. Prognostic and predictive relevance of tumor-infiltrating lymphocytes in squamous cell head-neck cancer patients treated with radical radiotherapy/chemo-radiotherapy[J]. Curr Oncol, 2022, 29(6): 4274-4284. DOI: 10.3390/curroncol29060342.
[38]	AOKI Y, TAKAKUWA K, KODAMA S, et al. Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer[J]. Cancer Res, 1991, 51(7): 1934-1939.
[39]	CHAMBERLAIN CA, BENNETT EP, KVERNELAND AH, et al. Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy[J]. Mol Ther Oncolytics, 2022, 24: 417-428. DOI: 10.1016/j.omto.2022.01.004.
[40]	ZHANG L, MORGAN RA, BEANE JD, et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma[J]. Clin Cancer Res, 2015, 21(10): 2278-2288. DOI: 10.1158/1078-0432.CCR-14-2085.
[41]	FORGET MA, TAVERA RJ, HAYMAKER C, et al. A novel method to generate and expand clinical-grade, genetically modified, tumor-infiltrating lymphocytes[J]. Front Immunol, 2017, 8: 908. DOI: 10.3389/fimmu.2017.00908.
[42]	GERARD CL, DELYON J, WICKY A, et al. Turning tumors from cold to inflamed to improve immunotherapy response[J]. Cancer Treat Rev, 2021, 101: 102227. DOI: 10.1016/j.ctrv.2021.102227.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (407) PDF downloads(97)

Research advances in tumor-infiltrating lymphocytes in treatment of biliary tract cancer

DOI: 10.3969/j.issn.1001-5256.2023.05.005

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Research advances in tumor-infiltrating lymphocytes in treatment of biliary tract cancer

DOI: 10.3969/j.issn.1001-5256.2023.05.005

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content